These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 28196367)

  • 1. Clinical Factors Predicting Tumour Upgrading in Patients Under Active Surveillance and Elected to Active Treatment after Disease Reclassification or Progression.
    Porcaro AB; Cavicchioli F; De Luyk N; Mattevi D; Corsi P; Sebben M; Tafuri A; Processali T; Inverardi D; Cacciamani G; De Marchi D; Balzarro M; Cerruto MA; Brunelli M; Novella G; Siracusano S; Artibani W
    Urol Int; 2017; 99(2):186-193. PubMed ID: 28196367
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Decade of Active Surveillance in the PRIAS Study: An Update and Evaluation of the Criteria Used to Recommend a Switch to Active Treatment.
    Bokhorst LP; Valdagni R; Rannikko A; Kakehi Y; Pickles T; Bangma CH; Roobol MJ;
    Eur Urol; 2016 Dec; 70(6):954-960. PubMed ID: 27329565
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prostate-specific antigen levels and proportion of biopsy positive cores are independent predictors of upgrading patterns in low-risk prostate cancer.
    Porcaro AB; Inverardi D; Corsi P; Sebben M; Cacciamani G; Tafuri A; Processali T; Pirozzi M; Mattevi D; De Marchi D; Amigoni N; Rizzetto R; Cerruto MA; Brunelli M; Siracusano S; Artibani W
    Minerva Urol Nefrol; 2020 Feb; 72(1):66-71. PubMed ID: 30298710
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pathological upgrading in prostate cancer patients eligible for active surveillance: Does prostate-specific antigen density matter?
    Jin BS; Kang SH; Kim DY; Oh HG; Kim CI; Moon GH; Kwon TG; Park JS
    Korean J Urol; 2015 Sep; 56(9):624-9. PubMed ID: 26366274
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pathologic Outcomes in Favorable-risk Prostate Cancer: Comparative Analysis of Men Electing Active Surveillance and Immediate Surgery.
    Tosoian JJ; Sundi D; Trock BJ; Landis P; Epstein JI; Schaeffer EM; Carter HB; Mamawala M
    Eur Urol; 2016 Apr; 69(4):576-581. PubMed ID: 26456680
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adverse Disease Features in Gleason Score 3 + 4 "Favorable Intermediate-Risk" Prostate Cancer: Implications for Active Surveillance.
    Morlacco A; Cheville JC; Rangel LJ; Gearman DJ; Karnes RJ
    Eur Urol; 2017 Sep; 72(3):442-447. PubMed ID: 27574819
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A biopsy-integrated algorithm for determining Gleason 6 upgrading risk stratifies risk of active surveillance failure in prostate cancer.
    Blute ML; Shiau JM; Truong M; Shi F; Abel EJ; Downs TM; Jarrard DF
    World J Urol; 2017 May; 35(5):729-735. PubMed ID: 27631325
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Refined Analysis of Prostate-specific Antigen Kinetics to Predict Prostate Cancer Active Surveillance Outcomes.
    Cooperberg MR; Brooks JD; Faino AV; Newcomb LF; Kearns JT; Carroll PR; Dash A; Etzioni R; Fabrizio MD; Gleave ME; Morgan TM; Nelson PS; Thompson IM; Wagner AA; Lin DW; Zheng Y
    Eur Urol; 2018 Aug; 74(2):211-217. PubMed ID: 29433975
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association between Basal Total Testosterone Levels and Tumor Upgrading in Low and Intermediate Risk Prostate Cancer.
    Porcaro AB; De Luyk N; Corsi P; Sebben M; Tafuri A; Processali T; Cerasuolo M; Mattevi D; Cerruto MA; Brunelli M; Siracusano S; Artibani W
    Urol Int; 2017; 99(2):215-221. PubMed ID: 28245478
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Active surveillance strategy for patients with localised prostate cancer: criteria for progression.
    Thomsen FB
    Dan Med J; 2015 Feb; 62(2):. PubMed ID: 25634510
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Final pathohistology after radical prostatectomy in patients eligible for active surveillance (AS).
    Lellig E; Gratzke C; Kretschmer A; Stief C
    World J Urol; 2015 Jul; 33(7):917-22. PubMed ID: 26047652
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The ability of prostate-specific antigen (PSA) density to predict an upgrade in Gleason score between initial prostate biopsy and prostatectomy diminishes with increasing tumour grade due to reduced PSA secretion per unit tumour volume.
    Corcoran NM; Casey RG; Hong MK; Pedersen J; Connolly S; Peters J; Harewood L; Gleave ME; Costello AJ; Hovens CM; Goldenberg SL
    BJU Int; 2012 Jul; 110(1):36-42. PubMed ID: 22085203
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Population-Based Assessment of Determining Treatments for Prostate Cancer.
    Chamie K; Williams SB; Hu JC
    JAMA Oncol; 2015 Apr; 1(1):60-7. PubMed ID: 26182305
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Active Surveillance for Prostate Cancer in a Real-life Cohort: Comparing Outcomes for PRIAS-eligible and PRIAS-ineligible Patients.
    Soeterik TFW; van Melick HHE; Dijksman LM; Biesma DH; Witjes JA; van Basten JA
    Eur Urol Oncol; 2018 Aug; 1(3):231-237. PubMed ID: 31102626
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Limitations in Predicting Organ Confined Prostate Cancer in Patients with Gleason Pattern 4 on Biopsy: Implications for Active Surveillance.
    Perlis N; Sayyid R; Evans A; Van Der Kwast T; Toi A; Finelli A; Kulkarni G; Hamilton R; Zlotta AR; Trachtenberg J; Ghai S; Fleshner NE
    J Urol; 2017 Jan; 197(1):75-83. PubMed ID: 27457260
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prostate-specific antigen vs prostate-specific antigen density as a predictor of upgrading in men diagnosed with Gleason 6 prostate cancer by contemporary multicore prostate biopsy.
    Oh JJ; Hong SK; Lee JK; Lee BK; Lee S; Kwon OS; Byun SS; Lee SE
    BJU Int; 2012 Dec; 110(11 Pt B):E494-9. PubMed ID: 22540236
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Incidence of upgrading and upstaging in patients with low-volume Gleason score 3+4 prostate cancers at biopsy: finding a new group eligible for active surveillance.
    Park HJ; Ha YS; Park SY; Kim YT; Lee TY; Kim JH; Lee DH; Kim WJ; Kim IY
    Urol Int; 2013; 90(3):301-5. PubMed ID: 23391718
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Older Age Predicts Biopsy and Radical Prostatectomy Grade Reclassification to Aggressive Prostate Cancer in Men on Active Surveillance.
    Druskin SC; Mamawala M; Tosoian JJ; Epstein JI; Pavlovich CP; Carter HB; Trock BJ
    J Urol; 2019 Jan; 201(1):98-104. PubMed ID: 30114397
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessing the relationship between statin use and oncologic outcomes among men electing active surveillance for localized prostate cancer.
    Nyame YA; Wilkins L; Greene DJ; Ganesan V; Dai C; Almassi N; Stephenson AJ; Gong M; Berglund R; Klein EA
    Prostate Cancer Prostatic Dis; 2019 Dec; 22(4):617-623. PubMed ID: 30996285
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development and multi-institutional validation of an upgrading risk tool for Gleason 6 prostate cancer.
    Truong M; Slezak JA; Lin CP; Iremashvili V; Sado M; Razmaria AA; Leverson G; Soloway MS; Eggener SE; Abel EJ; Downs TM; Jarrard DF
    Cancer; 2013 Nov; 119(22):3992-4002. PubMed ID: 24006289
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.